Several VEGFR-targeting multi-kinase inhibitors such as nintedanib, trebananib, pazopanib, sunitinib, sorafenib, cediranib have been tested in various phases of ovarian cancer clinical trials [9]. Here, KDR is linked to ovarian cancer.